Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922490 · ClinicalTrials.gov registry record · Phase 4
Lipogems Prospective Study
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03922490: Clinical Trial Phase 4 study, sponsored by Hospital for Special Surgery, New York.
NCT03922490 is a Phase 4 study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03922490, a Phase 4 study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to study the clinical outcomes and effects of the injection of fat-derived stem cells (the scientific name being "adipose derived autologous stem cell transplantation (ADAT)") as an addition to knee arthroscopy in the treatment of knee swelling and pain associated with mild to moderate knee osteoarthritis. Management of this condition remains a pervasive problem within orthopaedics. Lipogems is a Food and Drug Administration (FDA) approved technique. Lipogems is the name of the technology used to obtain stem cells from fat that will be aspirated/removed by suction from the abdomen. Fat will be processed to obtain stem cells which will then be injected into the knee after the physician completes knee arthroscopy. The study that we are asking patients to enroll in is important because it will attempt to answer the question about whether fat-derived stem cells added to knee arthroscopy is better, worse or no different than knee arthroscopy alone. Currently, without this study, we do not have an answer to this question.
Primary Outcome
Questions related to knee pain Scale range: 0-100 points (100 indicating no symptoms and 0 indicating extreme symptoms)
Interventions
- DEVICE Lipogems Device PLUS debridement
- PROCEDURE Debridement only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-11-11 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 4 |
Why NCT03922490 stopped before completion
NCT03922490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Lipogems Device PLUS debridement is the first listed.
NCT03922490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03922490 about?
NCT03922490 is a clinical study titled "Lipogems Prospective Study". The purpose of this study is to study the clinical outcomes and effects of the injection of fat-derived stem cells (the scientific name being "adipose derived autologous stem cell transplantation (ADAT)") as an addition to knee arthroscopy in the treatment of knee swelling and pain associated with m...
What is the current status of trial NCT03922490?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2019-11-11. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03922490?
The interventions under investigation include: Lipogems Device PLUS debridement (DEVICE), Debridement only (PROCEDURE).
Who is sponsoring clinical trial NCT03922490?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03922490's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI